

Supplementary Table 1. Frequency of Type of sample in Control group.

	control	Frequency	Percent
Valid	Anastomosis site stenosis, biopsy	1	2.8
	Colon	17	47.2
	Colon & rectal	1	2.8
	Colon biopsy	8	22.2
	Ileal & Colon biopsy	1	2.8
	Ileal biopsy	1	2.8
	LT Colon biopsy	1	2.8
	rectal	1	2.8
	Rectal biopsy	1	2.8
	Rectosigmoid biopsy	1	2.8
	Rectosigmoid Colon	1	2.8
	Sigmoidoscopy	1	2.8
	Total colectomy	1	2.8
	Total	36	100.0

Supplementary Table 2. Frequency of Type of case in Control group

	control	Frequency	Percent
Valid	Abnormal change (unreachable)	1	2.8
	Active chronic idiopathic (IBD)	2	5.6
	Active chronic idiopathic ulcerative colitis	1	2.8
	Adenomatous polyps	1	2.8
	Benign ileal & colon tumor	1	2.8
	Celiac disease & autoimmune enteropathy	1	2.8
	Chronic inflammation & multifocal villous atrophy	1	2.8
	Colonic polyps	12	33.3
	Congestion, crypt distraction by mixed inflammation & edema	1	2.8
	Congestion, few lymphoid aggregates& edema	1	2.8
	Congestion & edema	5	13.9
	Hirschsprung disease (hypo ganglionic type)	1	2.8
	Mild acute self-limited colitis	2	5.6
	Mild Congestion & edema	1	2.8
	Mild ileitis	1	2.8
	mucosal contestation	1	2.8
	mucosal contestation & lymphoid aggregates	1	2.8

	Ulcerative colitis (mild activity)	2	5.6
	Total	36	100.0

Supplementary Table 3. the expression level of *BRAF* gene in colon cancer patients

<i>groups</i>	<i>Means Ct of BRAF</i>	<i>Means Ct of GAPDH</i>	<i>ΔCt (Means Ct of BRAF)</i>	<i>2^{-ΔCt}</i>	<i>experimental group/ Control group</i>	<i>Fold of gene expression</i>	<i>P-value</i>
Patients	25.405	17.298	8.106666	0.0036	0.0036/0.0040	0.9070	0.01**
Control	25.842	17.869	7.9725	0.0040	0.0040/0.0040	1.000	

group, Supplementary Table 4.

Supplementary Table 4. The expression level of *Elastin* gene in colon cancer patients

<i>groups</i>	<i>Means Ct of Elastin</i>	<i>Means Ct of GAPDH</i>	ΔCt (<i>Means Ct of Elastin</i>)	$2^{-\Delta Ct}$	<i>experimental group/ Control group</i>	<i>Fold of gene expression</i>	<i>P-value</i>
Patients	28.204	17.298	10.90533	0.00052	0.00052 /0.01299	0.0401	0.001**
Control	24.136	17.869	6.26638	0.01299	0.01299/0.01299	1.0000	

Supplementary Table 5. The expression level of *TIMP3* gene in colon cancer patients

<i>groups</i>	<i>Means Ct of TIMP3</i>	<i>Means Ct of GAPDH</i>	ΔCt (<i>Means Ct of TIMP3</i>)	$2^{-\Delta Ct}$	<i>experimental group/ Control group</i>	<i>Fold of gene expression</i>	<i>P-value</i>
Patients	26.133	17.911	8.22177	0.00335	0.00335/0.00669	0.501	0.001**
Control	25.311	18.086	7.22416	0.00669	0.00669/0.00669	1.000	

Supplementary Table 6. The expression level of *K-ras* gene in colon cancer patients

<i>groups</i>	<i>Means Ct of Kras</i>	<i>Means Ct of GAPDH</i>	ΔCt (<i>Means Ct of Kras</i>)	$2^{-\Delta Ct}$	<i>experimental group/ Control group</i>	<i>Fold of gene expression</i>	<i>P-value</i>
Patients	22.633	17.911	4.721555	0.03790	0.03790/0.01823	2.079	0.01**
Control	23.864	18.086	5.77722	0.01823	0.01823/0.01823	1.000	

Supplementary Table 7. Comparison between patients IgG with expression level of BRAF, Elestin and TIMP3 genes.

IgG		BRAF	Elestin	TIMP3	K-RAS
Negative	Mean	0.9380	0.0428	0.6202	2.3675
	Std. Deviation	0.1498	0.0099	0.1095	0.9131
	Std. Error of Mean	0.0473	0.0031	0.0346	0.35851
Positive	Mean	0.9104	0.0414	0.4903	2.1649
	Std. Deviation	0.17104	0.01499	0.1238	0.70987
	Std. Error of Mean	0.0293	0.0025	0.0212	0.12174
P-value		0.6 NS	0.7 NS	0.005**	0.4 NS